Comparative Pharmacology
Head-to-head clinical analysis: VIBERZI versus XERMELO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIBERZI versus XERMELO.
VIBERZI vs XERMELO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guanylate cyclase-C agonist; increases intracellular cyclic guanosine monophosphate (cGMP) leading to activation of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid secretion and accelerated transit.
Telotristat ethyl is a prodrug that is hydrolyzed to the active metabolite telotristat, an inhibitor of tryptophan hydroxylase (TPH). TPH is the rate-limiting enzyme in the peripheral conversion of tryptophan to serotonin. By inhibiting TPH, telotristat reduces serotonin production in the gut, thereby decreasing gastrointestinal motility and secretion, and reducing diarrhea associated with carcinoid syndrome.
100 mg orally three times daily with meals.
250 mg orally three times daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 8-9 hours, supporting twice-daily dosing.
Terminal elimination half-life is approximately 6-10 hours in patients with carcinoid syndrome, supporting twice-daily dosing. In patients with moderate hepatic impairment, half-life may be prolonged to up to 19 hours.
Primarily fecal (approximately 95% of absorbed dose) with minimal renal excretion (<1%).
Primarily excreted via feces (approximately 82% of absorbed dose) with a minor renal component (approximately 12% of absorbed dose as unchanged drug and metabolites).
Category C
Category C
Antidiarrheal
Antidiarrheal